von Hippel-Lindau disease: genetic and clinical observations.
暂无分享,去创建一个
[1] Y. Xiong,et al. The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1 , 2000, Molecular and Cellular Biology.
[2] R. Conaway,et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[3] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[4] M. V. Heiden,et al. Redox regulation of p53 during hypoxia , 2000, Oncogene.
[5] P. Choyke,et al. Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. , 2000, The Journal of urology.
[6] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[7] B. Adryan,et al. Tracheal development and the von Hippel–Lindau tumor suppressor homolog in Drosophila , 2000, Oncogene.
[8] R. Rottapel,et al. Suppressor of Cytokine Signaling-1 Inhibits VAV Function through Protein Degradation* , 2000, The Journal of Biological Chemistry.
[9] K. Goss,et al. Biology of the adenomatous polyposis coli tumor suppressor. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Hurst,et al. Comparative sequence analysis of the VHL tumor suppressor gene. , 2000, Genomics.
[11] E. Lightcap,et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] G. Semenza. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. , 2000, Journal of applied physiology.
[13] Stephen Lee,et al. Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2* , 2000, The Journal of Biological Chemistry.
[14] S. Richard,et al. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease , 2000, Neurosurgical Review.
[15] Z. Ronai,et al. The SCFHOS/β-TRCP-ROC1 E3 Ubiquitin Ligase Utilizes Two Distinct Domains within CUL1 for Substrate Targeting and Ubiquitin Ligation , 2000, Molecular and Cellular Biology.
[16] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.
[17] J. Pouysségur,et al. Angiogenesis: how a tumor adapts to hypoxia. , 1999, Biochemical and biophysical research communications.
[18] S. Gottesman,et al. Posttranslational quality control: folding, refolding, and degrading proteins. , 1999, Science.
[19] R. Conaway,et al. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. , 1999, Genes & development.
[20] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[21] K. Roessler,et al. Multiple spinal “miliary” hemangioblastomas in von Hippel-Lindau (vHL) disease without cerebellar involvement , 1999, Neurosurgical Review.
[22] T. Shuin,et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. , 1999, Biochemical and biophysical research communications.
[23] R. Klausner,et al. The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.
[24] T. Stearns,et al. Components of an SCF ubiquitin ligase localize to the centrosome and regulate the centrosome duplication cycle. , 1999, Genes & development.
[25] H. Neumann,et al. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. , 1999, The Journal of clinical endocrinology and metabolism.
[26] Michele Pagano,et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.
[27] Wilhelm Krek,et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells , 1999, Nature Cell Biology.
[28] M. Gstaiger,et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. , 1999, Genes & development.
[29] W. Linehan,et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. , 1999, The New England journal of medicine.
[30] K Nasmyth,et al. Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. , 1999, Genes & development.
[31] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[32] H. Brauch,et al. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. , 1999, Journal of the National Cancer Institute.
[33] R. Kaufman,et al. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. , 1999, Genes & development.
[34] V. Sukhatme,et al. Transforming Growth Factor β1 Is a Target for the von Hippel-Lindau Tumor Suppressor and a Critical Growth Factor for Clear Cell Renal Carcinoma , 1999 .
[35] M. Scheffner,et al. Interaction between ubiquitin–protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation , 1999, Nature Cell Biology.
[36] S. Elledge,et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.
[37] W. Kaelin,et al. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.
[38] E. Yeh,et al. Identification of NEDD8-conjugation site in human cullin-2. , 1999, Biochemical and biophysical research communications.
[39] Z. Ronai,et al. Recruitment of a ROC1–CUL1 Ubiquitin Ligase by Skp1 and HOS to Catalyze the Ubiquitination of IκBα , 1999 .
[40] H. Zhu,et al. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. , 1999, Respiration physiology.
[41] B. Seizinger,et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity , 1999, Oncogene.
[42] R. Klausner,et al. Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein , 1999, Molecular and Cellular Biology.
[43] M. Gorospe,et al. Protective Function of von Hippel-Lindau Protein against Impaired Protein Processing in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.
[44] G. Semenza,et al. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.
[45] E. Ruoslahti,et al. Fibronectin and its integrin receptors in cancer. , 1999, Advances in cancer research.
[46] R. Deshaies. SCF and Cullin/Ring H2-based ubiquitin ligases. , 1999, Annual review of cell and developmental biology.
[47] R. Conaway,et al. Transcription elongation and human disease. , 1999, Annual review of biochemistry.
[48] J. Kere,et al. Long-Term Prognosis of Haemangioblastoma of the CNS: Impact of von Hippel-Lindau Disease , 1999, Acta Neurochirurgica.
[49] W. Kaelin,et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. , 1998, Genes & development.
[50] M. Mann,et al. Identification of the receptor component of the IκBα–ubiquitin ligase , 1998, Nature.
[51] K. Plate,et al. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function , 1998 .
[52] M. Wei,et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[53] D. Mukhopadhyay,et al. Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ* , 1998, The Journal of Biological Chemistry.
[54] B. Scheithauer,et al. Peripheral nerve hemangioblastoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[55] R. Sutton,et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. , 1998, British Journal of Cancer.
[56] W. Kaelin,et al. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[57] J. Gervais,et al. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[58] R. Burk,et al. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[59] L. Huang,et al. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .
[60] S. Libutti,et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. , 1998, The American journal of pathology.
[61] J. Adler,et al. Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. , 1998, Neurosurgery.
[62] R. Deshaies,et al. Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[63] Campello,et al. Haemangioblastoma of the central nervous system in von Hippel–Lindau disease , 1998, Journal of internal medicine.
[64] H. Neumann,et al. Genotype–phenotype correlations in von hippel–lindau disease , 1998, Journal of internal medicine.
[65] Goldfarb. Nephron‐sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel–Lindau disease , 1998, Journal of internal medicine.
[66] Lips,et al. The eye in von Hippel–Lindau disease. Long‐term follow‐up of screening and treatment: recommendations , 1998, Journal of internal medicine.
[67] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[68] K. Kinzler,et al. Landscaping the Cancer Terrain , 1998, Science.
[69] R. Conaway,et al. The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein. , 1998, Biochimica et biophysica acta.
[70] M. Goebl,et al. Modification of yeast Cdc53p by the ubiquitin-related protein rub1p affects function of the SCFCdc4 complex. , 1998, Genes & development.
[71] K Nasmyth,et al. Mass spectrometric analysis of the anaphase-promoting complex from yeast: identification of a subunit related to cullins. , 1998, Science.
[72] R. Klausner,et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[73] W. Linehan,et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. , 1998, Cancer research.
[74] W. Kaelin,et al. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.
[75] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[76] W. Linehan,et al. Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.
[77] H. Riezman. The Ins and Outs of Protein Translocation , 1997, Science.
[78] A. Bardelli,et al. "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. , 1997, Biochimica et biophysica acta.
[79] D. Mukhopadhyay,et al. The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways* , 1997, The Journal of Biological Chemistry.
[80] A. Vortmeyer,et al. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. , 1997, The American journal of pathology.
[81] H. Neumann,et al. Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome. , 1997, The Journal of clinical endocrinology and metabolism.
[82] L. Mechtler,et al. Spinal Leptomeningeal Hemangioblastomatosis in von Hippel‐Lindau Disease: Magnetic Resonance and Pathological Findings , 1997, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[83] D. Mukhopadhyay,et al. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.
[84] B. Ponder,et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. , 1997, Human molecular genetics.
[85] G. M. Glenn,et al. Epididymal cystadenomas in von Hippel-Lindau disease. , 1997, Urology.
[86] M. Emmert-Buck,et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. , 1997, Human pathology.
[87] W. Kaelin,et al. The Molecular Basis of Von Hippel-Lindau Disease , 1997, Molecular medicine.
[88] S. Richard,et al. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.
[89] W. Poon,et al. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. , 1997, American journal of clinical pathology.
[90] A. Kibel,et al. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. , 1997, Human pathology.
[91] W. Kaelin,et al. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. , 1997, Kidney international.
[92] J. Goldblatt,et al. Variable penetrance of familial pheochromocytoma associated with the von Hippel Lindau gene mutation, S68W , 1997 .
[93] P. Choyke,et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. , 1997, JAMA.
[94] M. Tan,et al. Phaeochromocytoma: a ten-year survey. , 1997, QJM : monthly journal of the Association of Physicians.
[95] D. Livingston,et al. Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α Subunit* , 1996, The Journal of Biological Chemistry.
[96] W. Linehan,et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. , 1996, The American journal of pathology.
[97] F. Duh,et al. Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene , 1996, Human Genetics.
[98] Y. Miyagi,et al. VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE. LOCALIZATION OF EXPRESSION BY IN SITU HYBRIDIZATION , 1996, The Journal of pathology.
[99] Virgil L. Woods,et al. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types , 1996, Nature Medicine.
[100] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[101] R. Conaway,et al. Characterization of Elongin C Functional Domains Required for Interaction with Elongin B and Activation of Elongin A* , 1996, The Journal of Biological Chemistry.
[102] M. Goldberg,et al. Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.
[103] R. Conaway,et al. The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex. , 1996, The EMBO journal.
[104] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[105] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[106] J. Jääskeläinen,et al. Gamma knife radiosurgery in 11 hemangioblastomas. , 1996, Journal of neurosurgery.
[107] K. Plate,et al. Pathology, genetics and cell biology of hemangioblastomas. , 1996, Histology and histopathology.
[108] P. Jackson. Cell cycle: Cull and destroy , 1996, Current Biology.
[109] G. Semenza,et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.
[110] R. Hofstra,et al. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. , 1996, The Journal of clinical endocrinology and metabolism.
[111] F. Chen,et al. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. , 1996, Journal of medical genetics.
[112] H. Höfler,et al. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe , 1996, Human Genetics.
[113] Stephen J. Elledge,et al. SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box , 1996, Cell.
[114] Edward T Kipreos,et al. cul-1 Is Required for Cell Cycle Exit in C. elegans and Identifies a Novel Gene Family , 1996, Cell.
[115] G. Reifenberger,et al. MUTATION OF THE VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM , 1996, The Journal of pathology.
[116] D. Kondziolka,et al. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. , 1996, International journal of radiation oncology, biology, physics.
[117] P. Schofield,et al. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. , 1996, Human molecular genetics.
[118] R. Klausner,et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. , 1996, Biochimica et biophysica acta.
[119] B. Ponder,et al. Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. , 1996, The Journal of clinical endocrinology and metabolism.
[120] A. Webster,et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. , 1996, Journal of medical genetics.
[121] R. Whitehouse,et al. A genetic register for von Hippel-Lindau disease. , 1996, Journal of medical genetics.
[122] P. Waber,et al. Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer. , 1996, Oncogene.
[123] R. Conaway,et al. Purification of RNA polymerase II general transcription factors from rat liver. , 1996, Methods in enzymology.
[124] S. Peltz,et al. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. , 1996, Annual review of biochemistry.
[125] W. Linehan,et al. Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.
[126] B. Zbar,et al. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. , 1996, The Journal of clinical endocrinology and metabolism.
[127] S. Chew,et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. , 1995, Journal of medical genetics.
[128] M. Ginsberg,et al. Integrin activation and cytoskeletal interaction are essential for the assembly of a fibronectin matrix , 1995, Cell.
[129] C. Bain,et al. Somatic mutations of von Hippel‐Lindau (VHL) tumor‐suppressor gene in european kidney cancers , 1995, International journal of cancer.
[130] Fan,et al. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. , 1995, Cancer research.
[131] A. Kibel,et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.
[132] William Arbuthnot Sir Lane,et al. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II , 1995, Science.
[133] J. Nadol,et al. Endolymphatic sac tumors: Histopathologic confirmation, clinical characterization, and implication in von hippel‐lindau disease , 1995, The Laryngoscope.
[134] William Arbuthnot Sir Lane,et al. Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[135] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[136] R. Klausner,et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[137] M. Goldberg,et al. Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.
[138] J. Richie,et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. , 1995, The Journal of urology.
[139] F. Latif,et al. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. , 1995, Oncogene.
[140] F. Duh,et al. Expression of the Von Hippel-Lindau Tumor Suppressor Gene, VHL, in Human Fetal Kidney and During Mouse Embryogenesis , 1995, Molecular Medicine.
[141] Roy Parker,et al. Degradation of mRNA in eukaryotes , 1995, Cell.
[142] K. Plate,et al. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.
[143] P. Choyke,et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. , 1995, Radiology.
[144] P. Choyke,et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. , 1995, The Journal of urology.
[145] B. Seizinger,et al. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. , 1995, Cancer research.
[146] G. Semenza,et al. Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.
[147] M. Kirschner,et al. Ubiquitination of the G1 cyclin Cln2p by a Cdc34p‐dependent pathway. , 1995, The EMBO journal.
[148] W. Linehan,et al. Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.
[149] C. O'Brien,et al. Supratentorial haemangioblastoma not associated with Von Hippel Lindau complex or polycythaemia: case report and literature review. , 1995, British journal of neurosurgery.
[150] A. Gregor,et al. Immunohistochemical and ultrastructural studies of stromal cells in hemangioblastoma. , 1995, Folia neuropathologica.
[151] W. Sly,et al. Human carbonic anhydrases and carbonic anhydrase deficiencies. , 1995, Annual review of biochemistry.
[152] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[153] J. Nelson,et al. The clinical and pathological manifestations of renal tumors in von Hippel-Lindau disease. , 1994, The Journal of urology.
[154] B. Seizinger,et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. , 1994, American journal of human genetics.
[155] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[156] A. Bardelli,et al. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. , 1994, Journal of biotechnology.
[157] T. Shuin,et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.
[158] R. Hené,et al. Von Hippel-Lindau disease: new strategies in early detection and treatment. , 1994, The American journal of medicine.
[159] M. Lerman,et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.
[160] T. Sugimura,et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. , 1994, Cancer research.
[161] T. Sugiyama,et al. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. , 1994, The Tohoku journal of experimental medicine.
[162] William Arbuthnot Sir Lane,et al. Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[163] J. Minna,et al. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. , 1994, Oncogene.
[164] Y Kubota,et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.
[165] D. Hough,et al. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. , 1994, AJR. American journal of roentgenology.
[166] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[167] M. Lerman,et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. , 1994, Human molecular genetics.
[168] M. Goldberg,et al. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. , 1994, The Journal of biological chemistry.
[169] Wilson Pd,et al. Renal progenitor cells: problems of definition, isolation and characterization. , 1994 .
[170] S. Richard,et al. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. , 1994, Advances in nephrology from the Necker Hospital.
[171] H. Neumann,et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. , 1993, The New England journal of medicine.
[172] R. Kuwano,et al. Expression of vascular endothelial growth factor in capillary hemangioblastoma. , 1993, Biochemical and biophysical research communications.
[173] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[174] M. Lush,et al. Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. , 1993, Human molecular genetics.
[175] M. Frydenberg,et al. Conservative renal surgery for renal cell carcinoma in von Hippel-Lindau's disease. , 1993, The Journal of urology.
[176] E Medico,et al. Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[177] G. H. Weiss,et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. , 1992, AJR. American journal of roentgenology.
[178] H. Brambs,et al. Pancreatic lesions in the von Hippel-Lindau syndrome. , 1991, Gastroenterology.
[179] J. Caro,et al. Secondary erythrocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumor. , 1991, Blood.
[180] J. Horton,et al. Von Hippel‐Lindau disease and erythrocytosis: Radioimmunoassay of erythropoietin in cyst fluid from a brainstem hemangioblastoma , 1991, Neurology.
[181] P. Choyke,et al. Central nervous system involvement in Von Hippel‐Lindau disease , 1991, Neurology.
[182] C. Scudamore,et al. Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease. , 1991, The American journal of surgical pathology.
[183] M. Walther,et al. Simple renal cysts, atypical renal cysts, and renal cell carcinoma in von Hippel-Lindau disease: a lectin and immunohistochemical study in six patients. , 1991, Modern Pathology.
[184] M. Ferguson-Smith,et al. Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.
[185] C. Johnson,et al. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. , 1990, AJR. American journal of roentgenology.
[186] R. Scully,et al. Papillary cystadenoma of the broad ligament in von Hippel-Lindau disease. , 1990, American journal of obstetrics and gynecology.
[187] Hsia Ye,et al. von Hippel-Lindau disease affecting 43 members of a single kindred. , 1989 .
[188] D. Solomon,et al. Renal pathology in von Hippel-Lindau disease. , 1988, Human pathology.
[189] J. Haines,et al. Von HippelLindau disease maps to the region of chromosome 3 associated with renal cell carcinoma , 1988, Nature.
[190] H. Zincke,et al. Renal cell carcinoma in von Hippel-Lindau syndrome. , 1987, The American journal of medicine.
[191] J. Adamson,et al. Polycythemia: mechanisms and management. , 1981, Annals of internal medicine.
[192] K. Alitalo,et al. FIBRONECTIN AND THE PERICELLULAR MATRIX OF NORMAL AND TRANSFORMED ADHERENT CELLS * , 1978, Annals of the New York Academy of Sciences.
[193] K. Melmon,et al. Lindau's disease: Review of the literature and study of a large kindred , 1964 .
[194] A. Lindau. ZUR FRAGE DER ANGIOMATOSIS RETINæ UND IHRER HIRNKOMPLIKATIONEN , 1926 .